Paradigm shift in inflammatory bowel disease management: precision medicine, artificial intelligence, and emerging therapies Caballero-Mateos, Antonio M. Cañadas De La Fuente, Guillermo Arturo Gros, Beatriz inflammatory bowel disease Crohn’s disease ulcerative colitis Inflammatory bowel disease (IBD) management stands at the cusp of a transformative era, with recent breakthroughs heralding a paradigm shift in treatment strategies. Traditionally, IBD therapeutics revolved around immunosuppressants, but the landscape has evolved significantly. Recent approvals of etrasimod, upadacitinib, mirikizumab, and risankizumab have introduced novel mechanisms of action, offering renewed hope for IBD patients. These medications represent a departure from the status quo, breaking years of therapeutic stagnation. Precision medicine, involving Artificial Intelligence, is a pivotal aspect of this evolution, tailoring treatments based on genetic profiles, disease characteristics, and individual responses. This approach optimizes treatment efficacy, and paves the way for personalized care. Yet, the rising cost of IBD therapies, notably biologics, poses challenges, impacting healthcare budgets and patient access. Ongoing research strives to assess cost-effectiveness, guiding policy decisions to ensure equitable access to advanced treatments. Looking ahead, the future of IBD management holds great promise. Emerging therapies, precision medicine, and ongoing research into novel targets promise to reshape the IBD treatment landscape. As these advances continue to unfold, IBD patients can anticipate a brighter future, one marked by more effective, personalized, and accessible treatments. 2025-03-04T07:34:54Z 2025-03-04T07:34:54Z 2025-02-25 journal article Caballero Mateos, A.M.; Cañadas de la Fuente, G.A.; Gros, B. Paradigm Shift in Inflammatory Bowel Disease Management: Precision Medicine, Artificial Intelligence, and Emerging Therapies. J. Clin. Med. 2025, 14, 1536. https://doi.org/ 10.3390/jcm14051536 https://hdl.handle.net/10481/102831 10.3390/jcm14051536 eng http://creativecommons.org/licenses/by/4.0/ open access Atribución 4.0 Internacional MDPI